Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Drug

Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome

Fineline Cube Apr 11, 2025

China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...

Company Deals

Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization

Fineline Cube Apr 11, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...

Company Drug

CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine

Fineline Cube Apr 11, 2025

China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...

Company Drug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Fineline Cube Apr 10, 2025

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...

Company Drug

Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China

Fineline Cube Apr 10, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...

Company Drug

HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome

Fineline Cube Apr 10, 2025

China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...

Company Drug

IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis

Fineline Cube Apr 10, 2025

China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...

Company Drug

Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China

Fineline Cube Apr 10, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis

Fineline Cube Apr 10, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy

Fineline Cube Apr 10, 2025

China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...

Company

GE Healthcare Appoints Jeannette Bankes as President and CEO of Patient Care Solutions

Fineline Cube Apr 10, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced this week the appointment of Jeannette Bankes as...

Company Medical Device

Wantai Bio’s Tuberculosis Test Kit Joins UNOPS StopTB Procurement List

Fineline Cube Apr 10, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its Tuberculosis infection...

Company Drug

B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam

Fineline Cube Apr 10, 2025

B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...

Company Drug

Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies

Fineline Cube Apr 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...

Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Posts pagination

1 … 204 205 206 … 690

Recent updates

  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.